Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial

BACKGROUND: Antiangiogenic therapy combined with chemotherapy could improve pathological complete response (pCR) for breast cancer. Apatinib is an oral tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2. We assessed the efficacy and safety of apatinib c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ciqiu, Zhang, Junsheng, Zhang, Yi, Ji, Fei, Chen, Yitian, Zhu, Teng, Zhang, Liulu, Gao, Hongfei, Yang, Mei, Li, Jieqing, Cheng, Minyi, Wang, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379563/
https://www.ncbi.nlm.nih.gov/pubmed/35983024
http://dx.doi.org/10.1177/17588359221118053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379563/
https://www.ncbi.nlm.nih.gov/pubmed/35983024
http://dx.doi.org/10.1177/17588359221118053

Ejemplares similares